MPL mutation effect on JAK2 46/1 haplotype frequency in JAK2V617F-negative myeloproliferative neoplasms

被引：21

作者：

Patnaik, M. M. ^{[1
]}

Lasho, T. L. ^{[1
]}

Finke, C. M. ^{[1
]}

Gangat, N. ^{[1
]}

Caramazza, D. ^{[2
]}

Siragusa, S. ^{[2
]}

Hanson, C. A. ^{[3
]}

Pardanani, A. ^{[1
]}

Tefferi, A. ^{[1
]}

机构：

[1] Mayo Clin, Dept Med, Div Hematol, Rochester, MN 55905 USA

[2] Policlin Univ Palermo, Cattedra & UO Ematol, Palermo, Italy

[3] Mayo Clin, Dept Lab Med, Div Hematopathol, Rochester, MN USA

来源：

LEUKEMIA | 2010年 / 24卷 / 04期

关键词：

CONFERS SUSCEPTIBILITY; ESSENTIAL THROMBOCYTHEMIA; PRIMARY MYELOFIBROSIS; POLYCYTHEMIA-VERA; REGARDLESS; DISORDERS; SURVIVAL; INFERIOR;

D O I：

10.1038/leu.2010.1

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：859 / 860

页数：3

共 12 条

[1] Mutations of ASXL1 gene in myeloproliferative neoplasms [J].

Carbuccia, N. ;

Murati, A. ;

Trouplin, V. ;

Brecqueville, M. ;

Adelaide, J. ;

Rey, J. ;

Vainchenker, W. ;

Bernard, O. A. ;

Chaffanet, M. ;

Vey, N. ;

Birnbaum, D. ;

Mozziconacci, M. J. .

LEUKEMIA, 2009, 23 (11) :2183-2186

[2] JAK2 haplotype is a major risk factor for the development of myeloproliferative neoplasms [J].

Jones, Amy V. ;

Chase, Andrew ;

Silver, Richard T. ;

Oscier, David ;

Zoi, Katerina ;

Wang, Y. Lynn ;

Cario, Holger ;

Pahl, Heike L. ;

Collins, Andrew ;

Reiter, Andreas ;

Grand, Francis ;

Cross, Nicholas C. P. .

NATURE GENETICS, 2009, 41 (04) :446-449

[3] A germline JAK2 SNP is associated with predisposition to the development of JAK2V617F-positive myeloproliferative neoplasms [J].

Kilpivaara, Outi ;

Mukherjee, Semanti ;

Schram, Alison M. ;

Wadleigh, Martha ;

Mullally, Ann ;

Ebert, Benjamin L. ;

Bass, Adam ;

Marubayashi, Sachie ;

Heguy, Adriana ;

Garcia-Manero, Guillermo ;

Kantarjian, Hagop ;

Offit, Kenneth ;

Stone, Richard M. ;

Gilliland, D. Gary ;

Klein, Robert J. ;

Levine, Ross L. .

NATURE GENETICS, 2009, 41 (04) :455-459

[4] The 'GGCC' haplotype of JAK2 confers susceptibility to JAK2 exon 12 mutation-positive polycythemia vera [J].

Olcaydu, D. ;

Skoda, R. C. ;

Looser, R. ;

Li, S. ;

Cazzola, M. ;

Pietra, D. ;

Passamonti, F. ;

Lippert, E. ;

Carillo, S. ;

Girodon, F. ;

Vannucchi, A. ;

Reading, N. S. ;

Prchal, J. T. ;

Ay, C. ;

Pabinger, I. ;

Gisslinger, H. ;

Kralovics, R. .

LEUKEMIA, 2009, 23 (10) :1924-1926

[5] A common JAK2 haplotype confers susceptibility to myeloproliferative neoplasms [J].

Olcaydu, Damla ;

Harutyunyan, Ashot ;

Jaeger, Roland ;

Berg, Tiina ;

Gisslinger, Bettina ;

Pabinger, Ingrid ;

Gisslinger, Heinz ;

Kralovics, Robert .

NATURE GENETICS, 2009, 41 (04) :450-454

[6] The JAK2 46/1 haplotype confers susceptibility to essential thrombocythemia regardless of JAK2V617F mutational status-clinical correlates in a study of 226 consecutive patients [J].

Pardanani, A. ;

Lasho, T. L. ;

Finke, C. M. ;

Gangat, N. ;

Wolanskyj, A. P. ;

Hanson, C. A. ;

Tefferi, A. .

LEUKEMIA, 2010, 24 (01) :110-114

[7] Host genetic variation contributes to phenotypic diversity in myeloproliferative disorders [J].

Pardanani, Animesh ;

Fridley, Brooke L. ;

Lasho, Terra L. ;

Gilliland, D. Gary ;

Tefferi, Ayalew .

BLOOD, 2008, 111 (05) :2785-2789

[8] MPL515 mutations in myeloproliferative and other myeloid disorders:: a study of 1182 patients [J].

Pardanani, Animesh D. ;

Levine, Ross L. ;

Lasho, Terra ;

Pikman, Yana ;

Mesa, Ruben A. ;

Wadleigh, Martha ;

Steensma, David P. ;

Elliott, Michelle A. ;

Wolanskyj, Alexandra R. ;

Hogan, William J. ;

McClure, Rebecca F. ;

Litzow, Mark R. ;

Gilliland, D. Gary ;

Tefferi, Ayalew .

BLOOD, 2006, 108 (10) :3472-3476

[9] Low JAK2V617F allele burden in primary myelofibrosis, compared to either a higher allele burden or unmutated status, is associated with inferior overall and leukemia-free survival [J].

Tefferi, A. ;

Lasho, T. L. ;

Huang, J. ;

Finke, C. ;

Mesa, R. A. ;

Li, C. Y. ;

Wu, W. ;

Hanson, C. A. ;

Pardanani, A. .

LEUKEMIA, 2008, 22 (04) :756-761

[10] Classification and diagnosis of myeloproliferative neoplasms: The 2008 World Health Organization criteria and point-of-care diagnostic algorithms [J].

Tefferi, A. ;

Vardiman, J. W. .

LEUKEMIA, 2008, 22 (01) :14-22

← 1 2 →